Patents by Inventor David Okrongly

David Okrongly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210318311
    Abstract: The present disclosure provides a rapid test for determining state of an infection (e.g., a coronavirus such as Covid-2019) in a subject. The test may include the steps of detecting of an antibody specific to the pathogen in a blood sample from the subject, and detecting and quantitating the level of at least one inflammatory biomarker in the same subject.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 14, 2021
    Inventor: David Okrongly
  • Publication number: 20210208146
    Abstract: Aspects of the disclosure relate to improved methods and systems for predicting prostate cancer pathology associated with adverse outcomes in patients determined to a primary Gleason Grade of 3.
    Type: Application
    Filed: May 3, 2019
    Publication date: July 8, 2021
    Inventors: DAVID OKRONGLY, YAN DONG
  • Publication number: 20170234882
    Abstract: The present invention generally relates, in some embodiments, to methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy.
    Type: Application
    Filed: December 9, 2015
    Publication date: August 17, 2017
    Applicant: Quanterix Corporation
    Inventors: David Wilson, David C. Duffy, David Hanlon, David Okrongly
  • Publication number: 20160258959
    Abstract: The present invention generally relates, in some embodiments, to methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy.
    Type: Application
    Filed: December 9, 2015
    Publication date: September 8, 2016
    Applicant: Quanterix Corporation
    Inventors: David Wilson, David C. Duffy, David Hanlon, David Okrongly
  • Publication number: 20140227720
    Abstract: The present invention generally relates, in some embodiments, to methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy.
    Type: Application
    Filed: June 8, 2012
    Publication date: August 14, 2014
    Applicant: Quanterix Corporation
    Inventors: David Wilson, David C. Duffy, David Hanlon, David Okrongly
  • Publication number: 20100173339
    Abstract: Methods for determining the appropriateness of anti-platelet therapy in a patient with a platelet-affected disease. The Mean Platelet Component value in a patient blood sample is determined corresponding to the patient's platelet activation status. A high platelet activation status indicates the appropriateness of anti-platelet therapy.
    Type: Application
    Filed: March 22, 2010
    Publication date: July 8, 2010
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: E. Sabrinah Chapman-Montgomery, David Okrongly, Andrew McGregor Grant, Charaf E. Ahnadi, Alan Wu, Andre Gervais
  • Patent number: 7723064
    Abstract: Methods are disclosed for monitoring patients utilizing Mean Platelet Component values during therapeutic intervention.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: May 25, 2010
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: E. Sabrinah Chapman-Montgomery, David Okrongly, Andrew McGregor Grant, Charaf E. Ahnadi, Alan Wu, Andre Gervais
  • Publication number: 20080311606
    Abstract: Methods for assessing patient risk for platelet-affected disease states are disclosed. Also disclosed are methods for predicting the appropriateness of platelet antagonist therapy, and for monitoring patients during therapeutic intervention or during a combined regimen of therapy and angioplasty.
    Type: Application
    Filed: July 26, 2005
    Publication date: December 18, 2008
    Applicant: Bayer Healthcare LLC
    Inventors: E. Sabrinah Chapman- Montgomery, David Okrongly, Andrew McGregor Grant, Charaf E. Ahnadi, Alan Wu, Andre Gervais
  • Patent number: 5286789
    Abstract: Methods and compositions are provided, where oligopeptides are produced on a transparent surface while retaining transparency by the cyclical addition of protected monomers. Reagents are specifically selected to allow for efficient reproducible addition, while maintaining transparency of the support. Linkers are provided which permit retention of the oligopeptide to the surface or release of the oligopeptide at completion of the preparation of the oligopeptide. The oligopeptide bound to the support finds use in diagnostic assays, as well as other application, while the free oligopeptides may be used in a variety of ways.
    Type: Grant
    Filed: April 2, 1993
    Date of Patent: February 15, 1994
    Assignee: Applied Immune Sciences, Inc.
    Inventors: David Okrongly, Brian R. Clark, Jack Spesard
  • Patent number: 5283034
    Abstract: A method and composition which permits sterilization of surfaces coupled with biologically active moieties by ionizing radiation is described. The protecting composition contains a surface-stabilizing agent which adheres to the surface and has a molecular weight.gtoreq.5 kd, and an oxygen radical scavenger which is preferably a di- or polysaccharide or reduced form thereof. In the method of the invention, a surface which is coupled to a biologically active agent is protected with the invention composition, dried to a moisture content of less than 1%, and then sterilized by ionizing radiation under standard conditions. The sterilized surfaces of the invention are particularly useful in the production of medical devices intended for extracorporeal use, particularly in cell-separation techniques.
    Type: Grant
    Filed: March 26, 1992
    Date of Patent: February 1, 1994
    Assignee: Applied Immune Sciences, Inc.
    Inventors: David A. Okrongly, Donald Lamons, Thomas B. Okarma
  • Patent number: 4933410
    Abstract: Uncrosslinked polystyrene surfaces are derivatized under Friedel-Crafts conditions in a tetramethylenesulfone solvent using a substituted N-hydroymethyl acetamide derivatizing agent. The substitutent is subject to nucleophilic substitution to allow for the binding of a wide variety of molecules, particularly specific binding pair members, to the surface. Clarity is maintained for monitoring observation of events on the surface through the polystyrene.
    Type: Grant
    Filed: March 29, 1989
    Date of Patent: June 12, 1990
    Assignee: Applied Immunesciences, Inc.
    Inventor: David Okrongly